Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease

World Journal of Hepatology

Volumn 7, Issue 8, 2015, Pages 1012-1019

  Souza Mello, Vanessa ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Beta oxidation; Insulin resistance; Lipogenesis; Non alcoholic fatty liver disease; Obesity; Peroxisome proliferator activated receptors; Treatment

Indexed keywords

EID: 84929728792     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i8.1012     Document Type: Editorial

References (72)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428 [PMID: 15836891 DOI: 10.1016/S0140-6736(05)66378-7]
2. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004; 2: 1048-1058 [PMID: 15625647 DOI: 10.1016/S1542-3565(04)00440-9]
3. De Minicis S, Day C, Svegliati-Baroni G. From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights. Curr Pharm Des 2013; 19: 5239-5249 [PMID: 23394093 DOI: 10.2174/13816128130303]
4. Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2013; 28 Suppl 4: 81-87 [PMID: 24251710 DOI: 10.1111/jgh.12244]
5. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14 Suppl 5: 242S-249S [PMID: 17021375 DOI: 10.1038/oby.2006.317]
6. Cerf ME. High fat diet modulation of glucose sensing in the beta-cell. Med Sci Monit 2007; 13: RA12-RA17 [PMID: 17179917 DOI: 10.1016/j.bbrc.2013.03.076]
7. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89-104 [PMID: 11296700 DOI: 10.1055/s-2001-12932]
8. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004; 24: 644-649 [PMID: 14715643 DOI: 10.1007/978-1-4614-0650-1_6]
9. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev 2007; 65: S57-S63 [PMID: 17605315 DOI: 10.1016/j. gastrohep.2012.02.005]
10. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007; 18: 184-195 [PMID: 17296492 DOI: 10.1016/j.jnutbio.2006.12.006]
11. Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients 2014; 6: 5679-5703 [PMID: 25514388 DOI: 10.3390/nu6125679]
12. Crescenzo R, Bianco F, Falcone I, Coppola P, Liverini G, Iossa S. Increased hepatic de novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in fructose. Eur J Nutr 2013; 52: 537-545 [PMID: 22543624 DOI: 10.1007/s00394-012-0356-y]
13. Mori T, Kondo H, Hase T, Murase T. Dietary phospholipids ameliorate fructose-induced hepatic lipid and metabolic abnormalities in rats. J Nutr 2011; 141: 2003-2009 [PMID: 21940513 DOI: 10.3945/jn.111.143602]
14. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012; 23: 351-363 [PMID: 22704720 DOI: 10.1016/j.tem.2012.05.001]
15. Hardwick JP, Osei-Hyiaman D, Wiland H, Abdelmegeed MA, Song BJ. PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Res 2009; 2009: 952734 [PMID: 20300478 DOI: 10.1155/2009/952734]
16. Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 2012; 123: 259-270 [PMID: 22420611 DOI: 10.1042/CS20110373]
17. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; 28 Suppl 1: 68-76 [PMID: 23855299 DOI: 10.1111/jgh.12212]
18. Mansour M. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Prog Mol Biol Transl Sci 2014; 121: 217-266 [PMID: 24373239 DOI: 10.1016/B978-0-12-800101-1.00007-7]
19. Oliveira LS, Santos DA, Barbosa-da-Silva S, Mandarim-de-Lacerda CA, Aguila MB. The inflammatory profile and liver damage of a sucrose-rich diet in mice. J Nutr Biochem 2014; 25: 193-200 [PMID: 24445044 DOI: 10.1016/j.jnutbio.2013.10.006]
20. Nakamura A, Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD. Int J Mol Sci 2013; 14: 21240-21257 [PMID: 24284392 DOI: 10.3390/ijms141121240]
21. Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 2010; 119: 239-250 [PMID: 20415664 DOI: 10.1042/CS20100061]
22. Neto-Ferreira R, Rocha VN, Souza-Mello V, Mandarim-de-Lacerda CA, de Carvalho JJ. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr 2013; 5: 32 [PMID: 23816341 DOI: 10.1186/1758-5996-5-32]
23. Serviddio G, Giudetti AM, Bellanti F, Priore P, Rollo T, Tamborra R, Siculella L, Vendemiale G, Altomare E, Gnoni GV. Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS One 2011; 6: e24084 [PMID: 21909411 DOI: 10.1371/journal. pone.0024084]
24. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 1998; 273: 23786-23792 [PMID: 9726988 DOI: 10.1074/jbc.273.37.23786]
25. Yu GS, Lu YC, Gulick T. Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase Ibeta gene promoters by fatty acid enzyme substrate. J Biol Chem 1998; 273: 32901-32909 [PMID: 9830040 DOI: 10.1074/jbc.273.49.32901]
26. Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005; 87: 81-86 [PMID: 15733741 DOI: 10.1016/j.biochi.2004.11.008]
27. Chien D, Dean D, Saha AK, Flatt JP, Ruderman NB. Malonyl-CoA content and fatty acid oxidation in rat muscle and liver in vivo. Am J Physiol Endocrinol Metab 2000; 279: E259-E265 [PMID: 10913024]
28. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001; 21: 193-230 [PMID: 11375435 DOI: 10.1146/annurev.nutr.21.1.19321/1/193]
29. Macdonald GA, Prins JB. Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2004; 19: 1335-1337 [PMID: 15610304 DOI: 10.1111/j.1440-1746.2004.03562.x]
30. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 2006; 43: 506-514 [PMID: 16496325 DOI: 10.1002/hep.21070]
31. Magliano DC, Bargut TC, de Carvalho SN, Aguila MB, Mandarimde-Lacerda CA, Souza-Mello V. Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice. PLoS One 2013; 8: e64258 [PMID: 23700465 DOI: 10.1371/journal.pone.0064258]
32. Bringhenti I, Ornellas F, Martins MA, Mandarim-de-Lacerda CA, Aguila MB. Early hepatic insult in the offspring of obese maternal mice. Nutr Res 2015; 35: 136-145 [PMID: 25582085 DOI: 10.1016/j.nutres.2014.11.006]
33. Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJ, Glatz JF, Bonen A. A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 2004; 279: 36235-36241 [PMID: 15161924 DOI: 10.1074/jbc.M400566200M400566200]
34. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, McKay R, Monia B, Shutter JR, Lindberg RA, Shulman GI, Veniant MM. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 2006; 55: 2042-2050 [PMID: 16804074 DOI: 10.2337/db05-0705]
35. Valenti L, Rametta R, Dongiovanni P, Maggioni M, Fracanzani AL, Zappa M, Lattuada E, Roviaro G, Fargion S. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008; 57: 1355-1362 [PMID: 18316359 DOI: 10.2337/db07-0714]
36. Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res 2014; 53: 124-144 [PMID: 24362249 DOI: 10.1016/j.plipres.2013.12.001]
37. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, Geerts A. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003; 124: 184-201 [PMID: 12512042 DOI: 10.1053/gast.2003.50015]
38. Tsukamoto H, She H, Hazra S, Cheng J, Wang J. Fat paradox of steatohepatitis. J Gastroenterol Hepatol 2008; 23 Suppl 1: S104-S107 [PMID: 18336651 DOI: 10.1111/j.1440-1746.2007.05294.x]
39. Schultz A, Neil D, Aguila MB, Mandarim-de-Lacerda CA. Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int J Mol Sci 2013; 14: 21873-21886 [PMID: 24196354 DOI: 10.3390/ijms141121873]
40. Xu J, Xiao G, Trujillo C, Chang V, Blanco L, Joseph SB, Bassilian S, Saad MF, Tontonoz P, Lee WN, Kurland IJ. Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. J Biol Chem 2002; 277: 50237-50244 [PMID: 12176975 DOI: 10.1074/jbc. M201208200M201208200]
41. Day CP. NASH-related liver failure: one hit too many? Am J Gastroenterol 2002; 97: 1872-1874 [PMID: 12190148 DOI: 10.1111/j.1572-0241.2002.05952.x]
42. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141-148 [PMID: 10408502 DOI: 10.1016/S0140-6736(98)10364-1]
43. Harrington WW, S Britt C, G Wilson J, O Milliken N, G Binz J, C Lobe D, R Oliver W, C Lewis M, M Ignar D. The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR Res 2007; 2007: 97125 [PMID: 17710237 DOI: 10.1155/2007/97125]
44. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435 [PMID: 11818483 DOI: 10.1146/annurev.med.53.082901.104018]
45. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4: 14 [PMID: 16168052 DOI: 10.1186/1475-2840-4-14]
46. Brady PS, Marine KA, Brady LJ, Ramsay RR. Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs. Biochem J 1989; 260: 93-100 [PMID: 2775196]
47. Liu S, Hatano B, Zhao M, Yen CC, Kang K, Reilly SM, Gangl MR, Gorgun C, Balschi JA, Ntambi JM, Lee CH. Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation. J Biol Chem 2011; 286: 1237-1247 [PMID: 21059653 DOI: 10.1074/jbc.M110.138115]
48. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL. Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor delta from Peroxisome proliferator-activated receptor gamma in the ob/ob mouse. Genome Med 2009; 1: 115 [PMID: 19968882 DOI: 10.1186/gm115]
49. Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Korn O, Maluenda F, Diaz JC, Rencoret G, Braghetto I, Castillo J, Poniachik J, Videla LA. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2009; 1792: 1080-1086 [PMID: 19733654 DOI: 10.1016/j.bbadis.2009.08.015]
50. Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab 2011; 96: 1424-1430 [PMID: 21325464 DOI: 10.1210/jc.2010-2129]
51. Chan SM, Sun RQ, Zeng XY, Choong ZH, Wang H, Watt MJ, Ye JM. Activation of PPARa ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 2013; 62: 2095-2105 [PMID: 23349482 DOI: 10.2337/db12-1397]
52. Kondo K, Sugioka T, Tsukada K, Aizawa M, Takizawa M, Shimizu K, Morimoto M, Suematsu M, Goda N. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a highfat-diet-induced fatty liver in mice. Adv Exp Med Biol 2010; 662: 77-82 [PMID: 20204774 DOI: 10.1007/978-1-4419-1241-1_10]
53. Bargut TC, Frantz ED, Mandarim-de-Lacerda CA, Aguila MB. Effects of a diet rich in n-3 polyunsaturated fatty acids on hepatic lipogenesis and beta-oxidation in mice. Lipids 2014; 49: 431-444 [PMID: 24627299 DOI: 10.1007/s11745-014-3892-9]
54. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-205 [PMID: 18261709 DOI: 10.1016/j.dld.2007.10.002]
55. Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol 2013; 5: 470-478 [PMID: 24073298 DOI: 10.4254/wjh.v5.i9.470]
56. Lalloyer F, Wouters K, Baron M, Caron S, Vallez E, Vanhoutte J, Baugé E, Shiri-Sverdlov R, Hofker M, Staels B, Tailleux A. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 2011; 31: 1573-1579 [PMID: 21474829 DOI: 10.1161/ATVBAHA.110.220525]
57. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 2006; 44: 732-741 [PMID: 16466828 DOI: 10.1016/j.jhep.2005.10.033]
58. Fernandes-Santos C, Carneiro RE, de Souza Mendonca L, Aguila MB, Mandarim-de-Lacerda CA. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Nutrition 2009; 25: 818-827 [PMID: 19268533 DOI: 10.1016/j.nut.2008.12.010]
59. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, Motomura K, Anania FA, Willson TM, Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275: 35715-35722 [PMID: 10969082 DOI: 10.1074/jbc. M006577200M006577200]
60. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-1940 [PMID: 12055599 DOI: 10.1053/gast.2002.33666]
61. Nakayama H, Otabe S, Yuan X, Ueno T, Hirota N, Fukutani T, Wada N, Hashinaga T, Yamada K. Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. Metabolism 2009; 58: 901-908 [PMID: 19394977 DOI: 10.1016/j.metabol.2009.03.004]
62. Phillips SA, Kung JT. Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol 2010; 10: 676-683 [PMID: 20810317 DOI: 10.1016/j.coph.2010.08.002]
63. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110 [PMID: 18503774 DOI: 10.1053/j.gastro.2008.03.078]
64. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-453 [PMID: 19877169 DOI: 10.1002/hep.23270]
65. Violi F, Cangemi R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 363: 1185-1186; author reply 1186 [PMID: 20857543 DOI: 10.1056/NEJMoa0907929]
66. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 2009; 29: 988-996 [PMID: 19386026 DOI: 10.1111/j.1478-3231.2009.02006.x]
67. Penna-de-Carvalho A, Graus-Nunes F, Rabelo-Andrade J, Mandarim-de-Lacerda CA, Souza-Mello V. Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan. Exp Physiol 2014; 99: 1663-1678 [PMID: 25326526 DOI: 10.1113/expphysiol.2014.081596]
68. Ye JM, Iglesias MA, Watson DG, Ellis B, Wood L, Jensen PB, Sørensen RV, Larsen PJ, Cooney GJ, Wassermann K, Kraegen EW. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003; 284: E531-E540 [PMID: 12556350 DOI: 10.1152/ajpendo.00299.2002284/3/E531]
69. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-191 [PMID: 16574099 DOI: 10.1016/j.ejphar.2006.02.028]
70. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 2007; 1771: 952-960 [PMID: 17560826 DOI: 10.1016/j.bbalip.2007.04.018]
71. Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem 2003; 278: 46261-46269 [PMID: 12966092 DOI: 10.1074/jbc.M307827200M307827200]
72. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105: 287-292 [PMID: 10675354 DOI: 10.1172/JCI8538]